Navigation Links
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Date:5/16/2013

1 Receptor Agonist Product Portfolios and R&D Pipelines

 

4 ) Interferon

a) INTERFERON alpha

 

• Interferon alpha sales 2012 of branded products in regulated markets

• 1st generation Interferon alpha-2a in regulated markets

• 1st generation Interferon alpha-2a in non-regulated markets

• Next generation Interferon alpha-2a in regulated markets

• Next generation Interferon alpha-2a in non-regulated markets and biosimilars

• 1st generation Interferon alpha-2b in regulated markets

• 1st generation Interferon alpha-2b in non-regulated markets and biosimilars

• Next generation Interferon alpha-2b in regulated markets

• Next generation Interferon alpha-2b in non-regulated markets and biosimilars

• Other Interferon alpha sub-types

• Interferon alpha with not specified sub-type – 1/2

• Purified natural human interferon alpha

 

b) Consensus INTERFERONs

c) INTERFERON beta

 

• Interferon beta sales 2012 of branded products in regulated markets

• 1st generation Interferon beta-1a in regulated markets

• 1st generation Interferon beta-1a in non-regulated markets and biosimilars

• 1st generation Interferon beta-1b in regulated markets

• 1st generation Interferon beta-1b in non-regulated markets and biosimilars

• 1st generation Interferon beta with not disclosed sub-type

• Next generation Interferon beta in regulated markets

• Purified natural human interferon beta

 

d) INTERFERON gamma

e) Other INTERFERONs

5 ) Insulin

 

• 2012 Sales of branded recombinant human insulins in regulated markets

• 2012 Sales of branded short-acting recombinant human insulin analogs in regulate
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
6. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
9. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Tobira Therapeutics, Inc. ... the development and commercialization of novel treatments for ... of its merger with Regado Biosciences, Inc. (NASDAQ: ... closing of the merger, Tobira raised $40 million ... investors and all current Tobira institutional investors, including ...
(Date:5/4/2015)... N.Y. , May 4, 2015  Traverse ... $250,000 cooperative research and development agreement (CRADA) with ... advance the development of TRB-N0224 for the treatment ... including dogs and cats.  Traverse Biosciences has also ... for the treatment and control of periodontal disease ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and ... to 100x better detail than the industry standard. ... light microscopy methods, it needed another medium to measure ... frame of reference because it represents the highest standard ... the earliest discovery days of Ultralight Histology was to ...
(Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
Breaking Biology Technology:Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2
... the University of Wisconsin-Madison continues to make stem-cell ... announced over the weekend, things aren't going so well ... , ,Hwang Woo-suk, a South Korean stem-cell researcher, fell ... surfaced that he fabricated stem-cell research results. , ,Originally, ...
... venture and angel investors has been "cleaned up" to ... , Act 255 is an incentives package for ... can apply for tax credits of 25 percent of ... signed by the governor on Wednesday, allows groups of ...
... an official summary that referred to the bill as introduced and ... enacted, the source code would be placed into escrow with the ... recount, but not open to the public. WTN very much regrets ... , Madison, Wis. Among the 15 bills governor Jim ...
Cached Biology Technology:Stem-cell controversies slow progress 2Voting machine source code must be available for review 2
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands by the following Segments: Face Biometrics, and ... Canada , Japan , ... Middle East & Africa , and ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Southern California biomedical engineer and cardiologist Tzung "John" ... help clinicians distinguish cardiac emergencies requiring immediate surgery ... change. Angiograms, images made by catheters inserted ... inside view of the interior surface ("lumen") of ...
... frogs and toads have existed for 360 million years and ... is threatening to make many of them extinct, according to ... . The fungus, Batrachochytrium dendrobatidis (Bd), ... in Central America and north-eastern Australia in the 1990,s. Bd ...
... National Institute of General Medical Sciences (NIGMS), part of ... million for grants in scientific areas it identified as ... to stimulate biomedical research and the economy using funds ... Act). "The GO grants fund projects that promise ...
Cached Biology News:Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Biology Products: